Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation

Cytokine

Volumn 61, Issue 3, 2013, Pages 808-815

  Díaz Delfín, Julieta ^a   Domingo, Pere ^b,c   Giralt, Marta ^a   Villarroya, Francesc ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adipocytes; Cytokines; Inflammation; Lipodystrophy; Maraviroc

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; EFAVIRENZ; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MARAVIROC; MESSENGER RNA; MITOCHONDRIAL DNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MITOCHONDRIAL TOXICITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADIPOCYTES; ADIPOGENESIS; ADIPOKINES; BIOLOGICAL MARKERS; CELLS, CULTURED; CYCLOHEXANES; CYTOKINES; DNA, MITOCHONDRIAL; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MITOCHONDRIA; RNA, MESSENGER; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84875376516     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.12.013     Document Type: Article

References (45)

1. Shafer R.W., Vuitton D.A. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother 1999, 53:73-86.
2. Kaplan J.E., Hanson D., Dworkin M.S., Frederick T., Bertolli J., Lindegren M.L., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30(Suppl 1):5-14.
3. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
4. Jain R.G., Furfine E.S., Pedneault L., White A.J., Lenhard J.M. Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001, 51:151-177.
5. Gougeon M.L., Pénicaud L., Fromenty B., Leclercq P., Viard J., Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antiviral Ther 2004, 9:161-177.
6. Caron-Debarle M., Lagathu C., Boccara F., Vigouroux C., Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010, 16:218-229.
7. El Hadri K., Glorian M., Monsempes C., Dieudonné M.N., Pecquery R., Giudicelli Y., et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem 2004, 279:15130-15141.
8. Lagathu C., Bastard J.P., Auclair M., Maachi M., Kornprobst M., Capeau J., et al. Anti-retroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antiviral Ther 2004, 9:911-920.
9. Villarroya F., Domingo P., Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int J Obes (London) 2007, 31:1763-1776.
10. Brenchley J.M., Price D.A., Schacker T.W., Asher T.E., Silvestri G., Rao S., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
11. Gimble J.M., Dorheim M.A., Cheng A., Medina K., Wang C.S., Jones R., et al. Adipogenesis in a murine bone marrow stromal cell line capable of supporting B lineage lymphocyte growth and proliferation: biochemical and molecular characterization. Eur J Immunol 1990, 20:379-387.
12. Stankov M.V., Behrens G.M. Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients. Curr Pharm Des 2010, 16:3361-3371.
13. Lalezari J., Thompson M., Kumar P., Piliero P., Davey R., Patterson K., et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 2005, 19:1443-1448.
14. Schürmann D., Fätkenheuer G., Reynes J., Michelet C., Raffi F., van Lier J., et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007, 21:1293-1299.
15. Owen S.M., Rudolph D., Schols D., Fujii N., Yamamoto N., Lal R.B. Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds. J Med Virol 2002, 68:147-155.
16. Lin P.F., Blair W., Wang T., Spicer T., Guo Q., Zhou N., et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003, 100:11013-11018.
17. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732.
18. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007, 81:2359-2371.
19. Mueller M.C., Bogner J.R. Treatment with CCR5 antagonists: which patient may have a benefit?. Eur J Med Res 2007, 12:441-452.
20. Hazan U., Romero I.A., Cancello R., Valente S., Perrin V., Mariot V., et al. Human adipose cells express CD4, CXCR4, and CCR5 [corrected] receptors: a new target cell type for the immunodeficiency virus-1?. FASEB J 2002, 6:1254-1256.
21. Gallego-Escuredo J.M., Del Mar Gutierrez M., Diaz-Delfin J., Domingo J.C., Mateo M.G., Domingo P., et al. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res 2010, 8:545-553.
22. Díaz-Delfín J., del Mar Gutiérrez M., Gallego-Escuredo J.M., Domingo J.C., Gracia Mateo M., Villarroya F., et al. Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res 2011, 91:112-119.
23. Díaz-Delfín J., Domingo P., Mateo M.G., Gutierrez M del M., Domingo J.C., Giralt M., et al. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrob Agents Chemother 2012, 56:3369-3375.
24. Lin Y., Lee H., Berg A.H., Lisanti M.P., Shapiro L., Scherer PE. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 2000, 275:24255-24263.
25. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001, 50:1378-1388.
26. Dowell P., Flexner C., Kwiterovich P.O., Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000, 275:41325-41332.
27. Díaz-Delfín J., Domingo P., Wabitsch M., Giralt M., Villarroya F. HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes. Antiviral Ther 2012, 17:529-540.
28. Shrivastav S., Kino T., Cunningham T., Ichijo T., Schubert U., Heinklein P., et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor gamma and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol 2008, 22:234-247.
29. Bulló M., Peeraully M.R., Trayhurn P., Folch J., Salas-Salvadó J. Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur J Endocrinol 2007, 157:303-310.
30. Bell L.N., Cai L., Johnstone B.H., Traktuev D.O., March K.L., Considine R.V. A central role for hepatocyte growth factor in adipose tissue angiogenesis. Am J Physiol Endocrinol Metab 2008, 294:E336-E344.
31. Funderburg N., Kalinowska M., Eason J., Goodrich J., Heera J., Mayer H., et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One 2010, 5:e13188.
32. Rossi R., Lichtner M., De Rosa A., Sauzullo I., Mengoni F., Massetti A.P., et al. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 2011, 166:184-190.
33. Cooper D.A., Heera J., Goodrich J., Tawadrous M., Saag M., Dejesus E., et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010, 201:803-813.
34. Asmuth D.M., Goodrich J., Cooper D.A., Haubrich R., Rajicic N., Hirschel B., et al. CD4+ T-cell restoration after 48weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010, 54:394-397.
35. Sweeney L.L., Brennan A.M., Mantzoros C.S. The role of adipokines in relation to HIV lipodystrophy. AIDS 2007, 21:895-904.
36. Tsiodras S., Perelas A., Wanke C., Mantzoros C.S. The HIV-1/HAART associated metabolic syndrome - novel adipokines, molecular associations and therapeutic implications. J Infect 2010, 61:101-113.
37. Sarraf P., Frederich R.C., Turner E.M., Ma G., Jaskowiak N.T., Rivet D.J., et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997, 185:171-175.
38. Gualillo O., Eiras S., Lago F., Diéguez C., Casanueva F.F. Elevated serum leptin concentrations induced by experimental acute inflammation. Life Sci 2000, 67:2433-2441.
39. Iikuni N., Lam Q.L., Lu L., Matarese G., La Cava A. Leptin and inflammation. Curr Immunol Rev 2008, 4:70-79.
40. Anderson P.D., Mehta N.N., Wolfe M.L., Hinkle C.C., Pruscino L., Comiskey L.L., et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007, 92:2272-2279.
41. Fätkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11:1170-1172.
42. Yilmaz A., Watson V., Else L., Gisslèn M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009, 23:2537-2540.
43. Tiraboschi J.M., Niubo J., Curto J., Podzamczer D. Maraviroc concentrations in seminal plasma in HIV-infected patients. J Acquir Immune Defic Syndr 2010, 55:e35-e36.
44. Melica G., Canestri A., Peytavin G., Lelievre J.D., Bouvier-Alias M., Clavel C., et al. Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms. AIDS 2010, 24:2130-2133.
45. Dupin N., Buffet M., Marcelin A.G., Lamotte C., Gorin I., Ait-Arkoub Z., et al. HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. AIDS 2002, 16:2419-2424.